Caplin Point Laboratories’ arm gets USFDA’s final approval for Carboprost Tromethamine Injection

14 Feb 2023 Evaluate

Caplin Point Laboratories’ subsidiary -- Caplin Steriles has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Carboprost Tromethamine Injection USP, 250 mcg/mL Single-dose Vials, a generic therapeutic equivalent version of (RLD), HEMABATE Injection, of Pfizer Inc.

Carboprost Tromethamine Injection USP is an oxytocic, indicated for the treatment of postpartum hemorrhage due to uterine atony. According to IQVIA (IMS Health), Carboprost Tromethamine Injection USP had US sales data of approximately $55 million for the 12-month period ending September 2022.

Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.

Caplin Point Lab Share Price

2478.35 -101.70 (-3.94%)
09-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1826.10
Dr. Reddys Lab 1371.60
Cipla 1488.15
Lupin 2251.80
Zydus Lifesciences 1009.40
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.